

PHARMACOLOGY

ADVANCES IN **PHARMACOLOGY**

VOLUME 44

Edited by

J. Thomas August

Department of Pharmacology
Johns Hopkins University
Baltimore, Maryland

M. W. Anders

Department of Pharmacology
University of Rochester
Rochester, New York

Ferid Murad

Department of Integrative Biology and Pharmacology
UT—Houston Medical School
Houston, Texas

Joseph T. Coyle

McLean Hospital
Harvard Medical School
Belmont, Massachusetts



ACADEMIC PRESS

San Diego London Boston New York Sydney Tokyo Toronto

This book is printed on acid-free paper. (∞)

Copyright © 1998 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-1997 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters.
1054-3589/98 \$25.00

Academic Press

a division of Harcourt Brace & Company

525 B Street, Suite 1900, San Diego, California 92101-4495, USA

<http://www.apnet.com>

Academic Press Limited

24-28 Oval Road, London NW1 7DX, UK

<http://www.hbuk.co.uk/ap/>

International Standard Book Number: 0-12-032945-X

PRINTED IN THE UNITED STATES OF AMERICA

98 99 00 01 02 03 QW 9 8 7 6 5 4 3 2 1

ADVANCES IN
PHARMACOLOGY

VOLUME 44

SERIAL EDITORS

J. Thomas August

Baltimore, Maryland

Ferid Murad

Houston, Texas

M. W. Anders

Rochester, New York

Joseph T. Coyle

Belmont, Massachusetts

ADVISORY BOARD

R. Wayne Alexander

Boston, Massachusetts

Floyd E. Bloom

La Jolla, California

Thomas F. Burke

Houston, Texas

Leroy Liu

Piscataway, New Jersey

Anthony R. Means

Durham, North Carolina

G. Alan Robison

Houston, Texas

John A. Thomas

San Antonio, Texas

Thomas C. Westfall

St. Louis, Missouri

Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

Graeme B. Bolger (225) Huntsman Cancer Institute, Veterans Affairs Medical Center, Departments of Medicine and Oncologic Science, University of Utah Health Sciences Center, Salt Lake City, Utah 84148

Maureen Cawley (1) Department of Pharmacy, Stanford Health Services, Stanford, California 94305

Andreas H. Groll (343) Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Joseph Hopkins (1) Division of Family and Community Medicine, Stanford University School of Medicine, Stanford, California 94305

Miles D. Houslay (225) Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow, Scotland G12 8QQ

Makoto Katori (147) Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan 228

Lawrence M. Kauvar (91) Terrapin Technologies, Inc., So. San Francisco, California 94080

L. J. Landells (33) The Sackler Institute of Pulmonary Pharmacology, Department of Respiratory Medicine, Kings College School of Medicine and Dentistry, London, England SE5 9PJ

Masataka Majima (147) Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan 228

- Daria Mochly-Rosen* (91) Department of molecular Pharmacology, Stanford University School of Medicine, Stanford, California 94305
- C. P. Page* (33) The Sackler Institute of Pulmonary Pharmacology, Department of Respiratory Medicine, Kings College School of Medicine and Dentistry, London, England SE5 9PJ
- Stephen C. Piscitelli* (343) Clinical Pharmacokinetic Research Laboratory, Clinical Pharmacy Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892
- Peter Rudd* (1) Division of General Internal Medicine, Stanford University School of Medicine, Stanford California 94305
- Shirley Siu* (1) Department of Pharmacy, Stanford Health Services, Stanford, California 94305
- D. Spina* (33) The Sackler Institute of Pulmonary Pharmacology, Department of Respiratory Medicine, Kings College School of Medicine and Dentistry, London, England SE5 9PJ
- Michael Sullivan* (225) Astra Charnwood, Loughborough, Leicestershire, United Kingdom LE11 5RH
- Thomas J. Walsh* (343) Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Contents

Contributors xi

Drug Therapy: The Impact of Managed Care

Joseph Hopkins, Shirley Siu, Maureen Cawley, and Peter Rudd

- I. Introduction 1
- II. Current Strategies to Contain Drug Costs 3
 - A. Pharmacy Benefits Managers 3
 - B. Formularies 5
 - C. Generic Prescribing and Substitution 6
 - D. Therapeutic Interchange 6
 - E. Drug-Use Review 7
 - F. Academic Detailing 8
 - G. Disease-State Management 9
 - H. Financial Incentives 11
 - I. Other Methods 12
- III. New Roles for Pharmacists 13
- IV. Selecting Desirable Drug-Prescribing Strategies in Managed Care 13
 - A. Quality 13
 - B. Cost 15
 - C. Value 16
 - D. Pharmacoeconomics 18
 - E. Importance of Compliance for Managed Care 18

V. Problems Confronting Current Strategies	20
A. Overemphasis on Immediate, Direct Cost Reduction	21
B. Formularies Fuel Resistance among Providers	22
C. Failure to Use Data to Implement Improvement in Care	22
D. Accountability of Disease-State Management Programs	23
E. Skepticism Regarding Quality-Improvement Methods	23
F. Potential Conflicts of Interest	24
VI. Summary	25
VII. Conclusions	26
References	27

The Role of Phosphodiesterase Enzymes in Allergy and Asthma

D. Spina, L. J. Landells, and C. P. Page

I. Introduction	33
II. Property and Classification of cAMP Phosphodiesterases	34
A. PDE1	36
B. PDE2	36
C. PDE3	36
D. PDE4	37
E. PDE5	41
F. PDE6	41
G. PDE7	41
H. PDE8	41
III. Role of PDEs in Regulation of Inflammatory Cell Function	42
A. Mast Cells and Basophils	42
B. Neutrophil	42
C. Eosinophil	43
D. T Lymphocyte	44
E. B Lymphocyte	46
F. Monocyte	47
G. Macrophage	48
H. Vascular Endothelium	49
I. Vascular Smooth Muscle	49
J. Airway Smooth Muscle	50
K. Other Cells	51
IV. Effects of PDE Inhibitors in Animal Models of Inflammation	52
A. Acute Bronchospasm	52
B. Recruitment of Inflammatory Cells	53
C. Bronchial Hyperresponsiveness	56
D. Airway Edema	58

- V. Role of PDE in Atopic Disease 60
 - A. Asthma 61
 - B. Atopic Dermatitis 65
- VI. Conclusion 69
- References 69

Modulating Protein Kinase C Signal Transduction

Daria Mochly-Rosen and Lawrence M. Kauvar

- I. Introduction 91
- II. Signal Transduction Networks 92
 - A. Clarifying Features 92
 - B. Specific Challenges 94
- III. Structural and Biochemical Studies 96
 - A. Primary Structure 97
 - B. Tertiary Structure 99
 - C. Substrates and Binding Partners 101
- IV. Pharmacological Probes 103
 - A. Natural Products 105
 - B. Activators 110
 - C. Inhibitors 112
 - D. Antisense 114
- V. PKC Physiology 115
 - A. Immunology 115
 - B. Oxidative Stress 118
 - C. Growth Control 120
 - D. Neurobiology 122
- VI. Anchoring Proteins 123
 - A. PKC Regulatory Domains Block Translocation 124
 - B. RACK Cloning 125
 - C. Pharmacology of Peptide Translocation Modulators 126
- VII. Prospects and Wider Implications 127
- References 128

Preventive Role of Renal Kallikrein–Kinin System in the Early Phase of Hypertension and Development of New Antihypertensive Drugs

Makoto Katori and Masataka Majima

- I. Renal Kallikrein–Kinin System 149
 - A. The Kallikrein–Kinin System 149
 - B. Full Set of Components of Kallikrein–Kinin System Expressed along Renal Distal Tubules 155

- II. Role of Renal Kallikrein–Kinin System 160
 - A. Background of Roles of Urinary Kallikrein–Kinin System 160
 - B. Stimuli for Kallikrein Secretion in Kidney 163
 - C. Studies on Rats with Congenital Deficiency of Kininogens in Plasma (BN-Ka Rats) 167
- III. Reduced Function of Renal Kallikrein–Kinin System in Hypertensive Patients and Hypertensive Models 176
 - A. Hypertensive Patients 176
 - B. Animal Models of Hypertension 179
 - C. Genetic Background 182
 - D. Sodium Accumulation Due to Failure of Renal Kinin Generation as a Cause of Hypertension 187
 - E. Difficulty of Secretion, Not Synthesis, of Renal Kallikrein in SHR 194
 - F. Possibility of Involvement of Cytoskeleton Protein with Point Mutation in Development of Hypertension 195
- IV. New Approaches to Drugs against Development of Hypertension 197
 - A. Inhibition of Kinin Degradation in Urine 197
 - B. Acceleration of Secretion of Renal Kallikrein 202
- V. Conclusion 204
- References 205

The Multienzyme PDE4 Cyclic Adenosine Monophosphate–Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions

Miles D. Houslay, Michael Sullivan, and Graeme B. Bolger

- I. Introduction 225
 - A. cAMP Signaling 225
 - B. Diversity of Cyclic Nucleotide Phosphodiesterases 227
 - C. Discovery of cAMP-Specific PDE4 Enzymes 229
- II. Molecular Cloning of PDE4 Isoenzymes 232
 - A. PDE4 Isoenzymes: A Multigene Family Enhanced by Alternative Splicing 232
 - B. *Dunce* PDE of *Drosophila melanogaster* 233
 - C. *Dunce* Gene of *Drosophila melanogaster* 234
- III. Mammalian PDE4 Gene Family 234
 - A. Nomenclature 241
 - B. Primary Structure of PDE4 Isoenzymes 241
 - C. Catalytic Unit 245
 - D. Upstream Conserved Regions 253

IV. Properties of PDE4 Isoforms	262
A. Size of PDE4 Isoenzymes on Sodium Dodecyl Sulfate–Polyacrylamide Gel	263
B. Purification of PDE4 Isoenzymes	265
C. Intracellular Targeting	267
D. Regulators of Catalytic Activity	283
V. Distribution of PDE4 Isoenzymes	299
A. Methods for Defining Which PDE4 Isoenzymes Are Expressed Natively in Specific Cell Types	299
B. Distribution of PDE4 Isoforms	299
C. Regulation of PDE4 Expression	301
VI. PDE4 Activity in Disease States	305
A. Aberrant Expression of PDE4 in Pathogenesis of Murine Nephrogenic Diabetes Insipidus	305
B. Neuronal Degeneration in Parkinson's Disease	307
C. Atopic Dermatitis	307
VII. Pharmacological Properties of Selective PDE4 Inhibitors: Potential Clinical Roles	308
A. Compounds That Serve as Selective PDE4 Inhibitors	308
B. PDE4 Inhibitors in Pharmacology of Depression	311
C. PDE4 Inhibitors in Treatment of Disorders of Vascular Tone	312
D. PDE4 Inhibitors in Treatment of Inflammatory States, Including Asthma	315
E. Contraindications of PDE4 Inhibitors	323
VIII. Conclusions	324
References	326

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Andreas H. Groll, Stephen C. Piscitelli, and Thomas J. Walsh

I. Introduction	343
II. Antifungal Drugs in Clinical Use	347
A. Amphotericin B	347
B. Lipid Formulations of Amphotericin B	357
C. Flucytosine	370
D. Antifungal Azoles	376
III. Antifungal Drugs under Clinical Investigation	395
A. Second-Generation Antifungal Triazoles	395
B. Third-Generation Antifungal Triazoles	401
C. Echinocandin Family of Antibiotics	407

D. Pradimicin Family of Antibiotics	415
E. Liposomal Nystatin	419
F. Polyoxins and Nikkomycins	420
G. Morpholines	422
H. Allylamines, Benzylamines, and Thiocarbamates	423
IV. Emerging Compounds and Targets	426
A. Fungal Cell Wall	426
B. Fungal Plasma Membrane	426
C. DNA and Protein Synthesis	431
D. Intermediary Metabolism	432
E. Other Cellular Functions	432
F. Virulence Factors	433
G. Gene Therapy	433
H. New Antifungal Antibiotics with Yet Unidentified Mechanisms of Action	433
V. Augmentation of Host Responses	434
A. Effects of Antifungal Compounds	434
B. Antifungal Vaccines and Antibodies	434
C. Cytokines and Reconstitution of Effector Cells	435
VI. Conclusions	438
References	438
Index	501

Joseph Hopkins*
Shirley Siu†
Maureen Cawley†
Peter Rudd‡

*Clinical Associate Professor of Medicine
Division of Family and Community Medicine
Stanford University School of Medicine
Medical Director for Health Plans
Stanford Health Services
Stanford, California 94305

†Department of Pharmacy
Stanford Health Services
Stanford, California 94305

‡Professor of Medicine
Chief, Division of General Internal Medicine
Stanford University School of Medicine
Stanford, California 94305

Drug Therapy: The Impact of Managed Care

I. Introduction

Health-care costs are high and rising. In the United States, estimates for health-care expenditures in 1993 exceeded \$900 billion, approaching 15% of the Gross Domestic Product (GDP). In 1995, the cost of drugs and other medical nondurables was projected to be \$84.7 billion, 7.1% of total national health expenditures (Burner and Waldo, 1995). Overall, the United States spends over \$3000 per person per year on health care (Smith, 1996).

A reorganization of health-care delivery is occurring. New activities of health-care consumers, providers, purchasers, and regulators now surround the core relationship between patients and providers (Fig. 1). In recent years, old paradigms of drug therapy have dramatically changed as alternative financing mechanisms for health care aimed at controlling cost have emerged. These changes are fueled by the rapid growth in national health expenditures, coupled with a decay in employer and public program confidence that pro-




FIGURE 1 Key participants in the managed-care setting. Multiple individuals and groups participate in the managed care framework: Purchasers, who may represent employers or other agencies, contract with managed-care organizations to provide health and medical care to enrollees, who come from the larger group of potential consumers of the services. The managed-care organization contracts with some physician Providers from a larger provider network. The key players are all subject to guidelines issued by regulators, who in turn impact both consumers and provider networks with both options and constraints.

viders alone would or could effectively address this problem. Under the generic label of “managed care,” these methods include discounted fee-for-service arrangements, incentives for patients to use lower cost “preferred providers,” and capitation of providers who are paid a fixed, prepaid amount each month to provide care for a defined group of patients. Collectively, these changes have led to a significant blunting of the annual rate of increase in real national health expenditures, to the point of approximating the rate of increase in the GDP for all goods and services in some recent years (Burner and Waldo, 1995).

Not surprisingly, drug costs, like other health-care costs, are being increasingly scrutinized for savings. A variety of strategies have successfully reduced drug price inflation from 6.9% in 1991 to 2.1% in 1995 (Santell, 1996). Many of these interventions seek to influence physician prescribing patterns. In surveys conducted at recent meetings of the American College of Physicians and the American College of Obstetricians and Gynecologists, two-thirds of physicians interviewed indicated they had received calls from their managed-care organizations and/or pharmacists asking them to change their prescribing habits (Anonymous, 1996b).

The focus of managed care on physicians’ prescribing is likely to intensify in the future, driven by two trends. First, technological advances will continue to bring new and expensive products to market, and, second, the progressive aging of the population will drive up medical-care utilization and costs (Burner and Waldo, 1995).

Despite the frequently negative press, careful review of studies of managed care has provided reassurance that systematic, organized approaches to care preserve or improve quality while reducing costs (Miller and Luft, 1994). The data supporting net benefit from pharmacy cost-containment strategies are much more limited, especially in assessing overall impact on longer term outcomes and overall costs. To assist physicians and pharmacists as active and informed participants in change, this chapter examines the array of practices aimed at control of drug costs to determine which may be the most desirable strategies.

II. Current Strategies to Contain Drug Costs _____

Approximately 60 to 70% of all drug utilization flows through a managed care organization. This is projected to increase to about 90% by the year 2000 (Covington, 1993). Multiple strategies are currently employed to contain drug costs at every level, from the purchase of pharmaceuticals from manufacturers, through distribution channels, to prescribing and dispensing. The strategies include the use of pharmacy benefits managers (PBMs), formularies, generic prescribing and substitution, therapeutic interchange, drug-use review, academic detailing, disease-state management (DSM), financial incentives, and new roles for pharmacists.

A. Pharmacy Benefits Managers

Increasingly, pharmaceutical companies market their products to managed-care companies instead of to physicians. In turn, managed-care insurance companies and provider groups, who have assumed financial risk under capitation payments, seek to reduce costs directly or contract with PBMs to assist them in structuring their pharmacy benefits and managing expenditures (Fig. 2).

PBMs initially developed as a way to implement prescription drug benefit programs for major employers, but by continually adapting and expanding their services, they have become nearly ubiquitous in managed care (Schulman *et al.*, 1996). PBM development was driven not only by unrest over escalating medical expenses and health-care reform, but also by the potential for using large computerized databases in standardized treatment protocols and pricing (Taniguchi, 1995; Weinstein *et al.*, 1996).

Pharmacy benefit management typically includes formulary management, generic-drug policies, drug-use review, counterdetailing, aggressive pricing contracts with the pharmaceutical industry, and mail-order prescription services (Taniguchi, 1995). Organizations can use these elements to manage cost and utilization (Schulman *et al.*, 1996). In the future, PBMs may have the ability to enter into risk-sharing contracts and compliance-




FIGURE 2 Managed pharmacy services. New organizations, activities, and programs (shown in ovals) have been added to the traditional participants (shown in boxes) in the delivery of pharmacy services. Mergers, acquisitions, affiliations, and contractual arrangements are creating increasing horizontal and vertical integration. PBM, pharmacy benefits manager; MCO, managed-care organization; DSM, disease-state management.

management programs and to employ sophisticated management information systems and DSM protocols (Siegel *et al.*, 1996; Taniguchi, 1995; Thomas, 1996).

In response, some pharmaceutical manufacturers have initiated different strategies, such as acquiring or merging or forming alliances with many of the intermediaries in the drug distribution industry (Navarro, 1994). In 1993, Merck & Co. determined that vertical integration through the purchase of Medco could preserve its threatened market share and profits and give itself access to patient-level outcomes databases (Larson and Bjornson, 1996; Muirhead, 1994; Taniguchi, 1995). This move led to a series of similar mergers (Pollard and Tilson, 1996). Within less than a year, the largest pharmaceutical benefits managers had been purchased by or formally allied with pharmaceutical manufacturers: (1) Eli Lilly acquired PCS Health Systems; (2) SmithKline Beecham purchased Diversified Pharmaceutical Services; (3) Caremark allied with Pfizer and Rhone-Poulenc Rorer; and (4) ValueRx allied with Pfizer. The pharmaceutical industry appears to be poised for further consolidation, in which companies integrate horizontally with each other and vertically with other members of the drug distribution and health-care system (O'Leary, 1995).